Eskil Eskilsson

3.3k total citations
7 papers, 304 citations indexed

About

Eskil Eskilsson is a scholar working on Molecular Biology, Genetics and Cancer Research. According to data from OpenAlex, Eskil Eskilsson has authored 7 papers receiving a total of 304 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 5 papers in Genetics and 5 papers in Cancer Research. Recurrent topics in Eskil Eskilsson's work include Glioma Diagnosis and Treatment (5 papers), Cancer, Hypoxia, and Metabolism (3 papers) and Angiogenesis and VEGF in Cancer (2 papers). Eskil Eskilsson is often cited by papers focused on Glioma Diagnosis and Treatment (5 papers), Cancer, Hypoxia, and Metabolism (3 papers) and Angiogenesis and VEGF in Cancer (2 papers). Eskil Eskilsson collaborates with scholars based in United States, Norway and Luxembourg. Eskil Eskilsson's co-authors include Roel G.W. Verhaak, Hrvoje Miletić, Rolf Bjerkvig, Grazia Graziani, Patrick N. Harter, Qianghu Wang, Gergely Solecki, Gro Vatne Røsland, Frank Winkler and Stefania D’Atri and has published in prestigious journals such as Neuro-Oncology, Frontiers in Oncology and Journal of Experimental & Clinical Cancer Research.

In The Last Decade

Eskil Eskilsson

7 papers receiving 303 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Eskil Eskilsson United States 5 160 145 84 82 63 7 304
Kirsten Ludwig United States 5 171 1.1× 205 1.4× 152 1.8× 85 1.0× 50 0.8× 9 393
Hayley Ellis United Kingdom 7 190 1.2× 202 1.4× 110 1.3× 102 1.2× 41 0.7× 11 391
Stephen V. Carney United States 8 168 1.1× 146 1.0× 68 0.8× 61 0.7× 46 0.7× 12 310
Larraitz Egaña Spain 8 119 0.7× 191 1.3× 154 1.8× 71 0.9× 42 0.7× 10 329
Johanna Buchroithner Austria 8 192 1.2× 222 1.5× 123 1.5× 146 1.8× 59 0.9× 13 451
Patrícia Domingues Portugal 3 172 1.1× 165 1.1× 107 1.3× 81 1.0× 104 1.7× 10 390
Yin-sheng Chen China 9 119 0.7× 181 1.2× 137 1.6× 99 1.2× 40 0.6× 11 341
Luyan Mu China 12 107 0.7× 188 1.3× 137 1.6× 106 1.3× 63 1.0× 20 383
Madison Butler United States 4 136 0.8× 120 0.8× 82 1.0× 39 0.5× 50 0.8× 8 256
Sébastien Bougnaud Norway 8 153 1.0× 189 1.3× 124 1.5× 127 1.5× 30 0.5× 12 398

Countries citing papers authored by Eskil Eskilsson

Since Specialization
Citations

This map shows the geographic impact of Eskil Eskilsson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eskil Eskilsson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eskil Eskilsson more than expected).

Fields of papers citing papers by Eskil Eskilsson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eskil Eskilsson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eskil Eskilsson. The network helps show where Eskil Eskilsson may publish in the future.

Co-authorship network of co-authors of Eskil Eskilsson

This figure shows the co-authorship network connecting the top 25 collaborators of Eskil Eskilsson. A scholar is included among the top collaborators of Eskil Eskilsson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eskil Eskilsson. Eskil Eskilsson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

7 of 7 papers shown
1.
Modrek, Aram S., Eskil Eskilsson, Ravesanker Ezhilarasan, et al.. (2022). PDPN marks a subset of aggressive and radiation-resistant glioblastoma cells. Frontiers in Oncology. 12. 941657–941657. 5 indexed citations
2.
Wu, Wei, Lingxiang Wu, Mengyan Zhu, et al.. (2018). miRNA Mediated Noise Making of 3′UTR Mutations in Cancer. Genes. 9(11). 545–545. 7 indexed citations
3.
Radke, Josefine, Eskil Eskilsson, Emmanuel Martínez-Ledesma, et al.. (2017). Prognostic Relevance of Tumor Purity and Interaction with MGMT Methylation in Glioblastoma. Molecular Cancer Research. 15(5). 532–540. 25 indexed citations
4.
Atzori, Maria Grazia, Lucio Tentori, Federica Ruffini, et al.. (2017). The anti-vascular endothelial growth factor receptor-1 monoclonal antibody D16F7 inhibits invasiveness of human glioblastoma and glioblastoma stem cells. Journal of Experimental & Clinical Cancer Research. 36(1). 106–106. 42 indexed citations
5.
Eskilsson, Eskil, Gro Vatne Røsland, Gergely Solecki, et al.. (2017). EGFR heterogeneity and implications for therapeutic intervention in glioblastoma. Neuro-Oncology. 20(6). 743–752. 222 indexed citations
6.
Miletić, Hrvoje, Krishna M. Talasila, Eskil Eskilsson, et al.. (2014). TM-14 * THE ANGIOGENIC SWITCH LEADS TO A METABOLIC SWITCH IN HUMAN GLIOBLASTOMA. Neuro-Oncology. 16(suppl 5). v216–v216. 2 indexed citations
7.
Eskilsson, Eskil, Krishna M. Talasila, Lina Leiss, et al.. (2014). AI-10 * DISTINCT EGFR SIGNALING IN GLIOBLASTOMA: WILD-TYPE EGFR PROMOTES INVASION WHILE EGFRvIII DRIVES PROTOTYPICAL SFK c-SRC ACTIVATION TO FOSTER ANGIOGENESIS. Neuro-Oncology. 16(suppl 5). v3–v3. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026